Yazhou He1, Xue Li2, Danijela Gasevic3, Eleanor Brunt4, Fiona McLachlan4, Marisa Millenson5, Maria Timofeeva2, John P A Ioannidis6, Harry Campbell2, Evropi Theodoratou2. 1. University of Edinburgh, Edinburgh, United Kingdom, and Sichuan University West China School of Medicine, Chengdu, People's Republic of China (Y.H.). 2. University of Edinburgh, Edinburgh, United Kingdom (X.L., M.T., H.C., E.T.). 3. University of Edinburgh, Edinburgh, United Kingdom, and Monash University, Melbourne, Victoria, Australia (D.G.). 4. University of Edinburgh Medical School, Edinburgh, United Kingdom (E.B., F.M.). 5. Brown University, Providence, Rhode Island (M.M.). 6. Stanford University School of Medicine and Stanford University, Stanford, California (J.P.I.).
Abstract
Background: Many effects of statins on non-cardiovascular disease (non-CVD) outcomes have been reported. Purpose: To evaluate the quantity, validity, and credibility of evidence regarding associations between statins and non-CVD outcomes and the effects of statins on these outcomes. Data Sources: MEDLINE and EMBASE (English terms only, inception to 28 May 2018). Study Selection: Meta-analyses (published in English) of observational studies and of randomized controlled trials (RCTs) that examined non-CVD outcomes of statin intake. Data Extraction: Two investigators extracted data from meta-analyses and individual studies. Credibility assessments based on summary effect sizes from a random-effects model, between-study heterogeneity, 95% prediction interval, small-study effect, excess significance, and credibility ceilings were devised to classify evidence. Data Synthesis: This review explored 278 unique non-CVD outcomes from 112 meta-analyses of observational studies and 144 meta-analyses of RCTs. For observational studies, no convincing (class I) evidence, 2 highly suggestive (class II) associations (decreased cancer mortality in patients with cancer and decreased exacerbation in patients with chronic obstructive pulmonary disease), 21 suggestive (class III) associations, and 42 weak (class IV) associations were identified. One outcome from the RCTs (decreased all-cause mortality in patients with chronic kidney disease) attained a sufficient amount of evidence with no hints of bias. For adverse events, observational studies showed suggestive evidence that statins increase the risk for diabetes and myopathy. Among the RCTs, no statistically significant effects were found on myopathy, myalgia, or rhabdomyolysis. Limitations: Studies with relevant data and outcomes not included in the meta-analyses may have been missed. Credibility assessments relied on several assumptions and arbitrary thresholds. Conclusion: The absence of convincing evidence of an association between statins and non-CVD outcomes supports leaving the current recommendations unchanged. Primary Funding Source: None.
Background: Many effects of statins on non-cardiovascular disease (non-CVD) outcomes have been reported. Purpose: To evaluate the quantity, validity, and credibility of evidence regarding associations between statins and non-CVD outcomes and the effects of statins on these outcomes. Data Sources: MEDLINE and EMBASE (English terms only, inception to 28 May 2018). Study Selection: Meta-analyses (published in English) of observational studies and of randomized controlled trials (RCTs) that examined non-CVD outcomes of statin intake. Data Extraction: Two investigators extracted data from meta-analyses and individual studies. Credibility assessments based on summary effect sizes from a random-effects model, between-study heterogeneity, 95% prediction interval, small-study effect, excess significance, and credibility ceilings were devised to classify evidence. Data Synthesis: This review explored 278 unique non-CVD outcomes from 112 meta-analyses of observational studies and 144 meta-analyses of RCTs. For observational studies, no convincing (class I) evidence, 2 highly suggestive (class II) associations (decreased cancer mortality in patients with cancer and decreased exacerbation in patients with chronic obstructive pulmonary disease), 21 suggestive (class III) associations, and 42 weak (class IV) associations were identified. One outcome from the RCTs (decreased all-cause mortality in patients with chronic kidney disease) attained a sufficient amount of evidence with no hints of bias. For adverse events, observational studies showed suggestive evidence that statins increase the risk for diabetes and myopathy. Among the RCTs, no statistically significant effects were found on myopathy, myalgia, or rhabdomyolysis. Limitations: Studies with relevant data and outcomes not included in the meta-analyses may have been missed. Credibility assessments relied on several assumptions and arbitrary thresholds. Conclusion: The absence of convincing evidence of an association between statins and non-CVD outcomes supports leaving the current recommendations unchanged. Primary Funding Source: None.
Authors: Ciaran N Kohli-Lynch; Brandon K Bellows; George Thanassoulis; Yiyi Zhang; Mark J Pletcher; Eric Vittinghoff; Michael J Pencina; Dhruv Kazi; Allan D Sniderman; Andrew E Moran Journal: JAMA Cardiol Date: 2019-10-01 Impact factor: 14.676
Authors: Tai Lim Kim; Gwang Hun Jeong; Jae Won Yang; Keum Hwa Lee; Andreas Kronbichler; Hans J van der Vliet; Giuseppe Grosso; Fabio Galvano; Dagfinn Aune; Jong Yeob Kim; Nicola Veronese; Brendon Stubbs; Marco Solmi; Ai Koyanagi; Sung Hwi Hong; Elena Dragioti; Eunyoung Cho; Leandro F M de Rezende; Edward L Giovannucci; Jae Il Shin; Gabriele Gamerith Journal: Adv Nutr Date: 2020-11-16 Impact factor: 8.701
Authors: Emily Herrett; Elizabeth Williamson; Kieran Brack; Alexander Perkins; Andrew Thayne; Haleema Shakur-Still; Ian Roberts; Danielle Prowse; Danielle Beaumont; Zahra Jamal; Ben Goldacre; Tjeerd van Staa; Thomas M MacDonald; Jane Armitage; Michael Moore; Maurice Hoffman; Liam Smeeth Journal: Health Technol Assess Date: 2021-03 Impact factor: 4.014
Authors: Ciaran N Kohli-Lynch; James Lewsey; Kathleen A Boyd; Dustin D French; Neil Jordan; Andrew E Moran; Naveed Sattar; David Preiss; Andrew H Briggs Journal: Circulation Date: 2022-03-07 Impact factor: 39.918
Authors: Shehnaz K Hussain; Asieh Golozar; Daniel P Widney; Giovanna Rappocciolo; Sudhir Penugonda; Jay H Bream; Otoniel Martínez-Maza; Lisa P Jacobson Journal: AIDS Res Hum Retroviruses Date: 2020-12-29 Impact factor: 1.723
Authors: Ge Liu; Mingjian Shi; Jonathan D Mosley; Chunhua Weng; Yanfei Zhang; Ming Ta Michael Lee; Gail P Jarvik; Hakon Hakonarson; Bahram Namjou-Khales; Patrick Sleiman; Yuan Luo; Frank Mentch; Joshua C Denny; MacRae F Linton; Wei-Qi Wei; C Michael Stein; QiPing Feng Journal: JAMA Netw Open Date: 2021-06-01
Authors: Perrine Janiaud; Arnav Agarwal; Ioanna Tzoulaki; Evropi Theodoratou; Konstantinos K Tsilidis; Evangelos Evangelou; John P A Ioannidis Journal: BMC Med Date: 2021-07-06 Impact factor: 11.150